Key result
Semaglutide increases cardiomyocyte viability ~27% following hypoxia/reoxygenation injury.
Why the study?
Semaglutide shows potential in cardiovascular protection, but its specific role and mechanism in hypoxia/reoxygenation (H/R) injury remain unclear.
Does semaglutide protect AC16 cardiomyocytes from hypoxia/reoxygenation injury?
Does semaglutide protect AC16 cardiomyocytes from hypoxia/reoxygenation injury?
Absolute Event Rate: 82.62% vs 64.94%
p-value: p=<0.05
Semaglutide protects cardiomyocytes from hypoxia/reoxygenation injury by mitigating oxidative stress, inflammation, and apoptosis through the promotion of autophagy.
Should not change practice; hypothesis-generating for semaglutide in cardiomyocyte hypoxia/reoxygenation.
Objective: Semaglutide shows potential in cardiovascular protection, yet its specific role and mechanism in H/R injury are unclear. Given the role of autophagy in cardiomyocyte protection and the unclear mechanism of semaglutide in H/R - induced injury, this study aims to assess semaglutide’s protective effects on AC16 cardiomyocytes in an H/R model and probe its mechanism, focusing on autophagy. Methods: AC16 cardiomyocytes were subjected to H/R to simulate H/R injury. Cells were divided into five groups: Control, H/R, H/R+Semaglutide, H/R+ Semaglutide+Rapamycin (autophagy activator), and H/R+Semaglutide+3-Methyladenine (3-MA, autophagy inhibitor). Cell viability, injury (LDH release), oxidative stress (MDA, SOD), and inflammation (IL-6, TGF-β) were assessed. Protein levels of cleaved caspase-3, caspase-9, Bax, Bcl-2, and the autophagy-related protein FUNDC1 were analyzed by Western blot. Results: H/R treatment significantly decreased cell viability and increased LDH release, indicating severe cellular injury ( P < 0.05). Semaglutide treatment effectively restored cell viability and reduced LDH release. Furthermore, Semaglutide significantly attenuated H/R-induced oxidative stress, as shown by decreased MDA levels and restored SOD activity ( P < 0.05). The inflammatory response, characterized by elevated IL-6 and TGF-β, was also markedly suppressed by Semaglutide ( P < 0.05). Flow cytometry analysis revealed that Semaglutide significantly reduced the apoptosis rate. Western blotting confirmed that Semaglutide downregulated pro-apoptotic proteins (cleaved caspase-3, caspase-9, Bax) and upregulated the anti-apoptotic protein Bcl-2. Importantly, Semaglutide increased the expression of FUNDC1. The protective effects were enhanced by Rapamycin and attenuated by 3-MA, indicating that autophagy is involved in the cardioprotection. Conclusion: Semaglutide shows substantial protective efficacy in safeguarding AC16 from H/R-triggered injury. It operates by mitigating oxidative stress, dampening inflammatory processes, inhibiting apoptotic pathways. Importantly, this investigation revealed that the cardioprotective effect, to a considerable degree, mediated through its promotion of autophagy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied Human AC16 cardiomyocytes subjected to hypoxia/reoxygenation injury in vitro. Semaglutide vs. Hypoxia/reoxygenation only was evaluated on Cell viability assessed by CCK-8 assay after hypoxia/reoxygenation injury (p=<0.05). Semaglutide at 5 mmol/L increased AC16 cardiomyocyte viability from 64.94% to 82.62% following hypoxia/reoxygenation injury (P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: